TransCode Therapeutics, Inc. (RNAZ) shares surged 20.70 percent, rising $2.53 to $14.75 on Wednesday, after announcing the acquisition of Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage melanoma vaccine candidate. The company also secured a $25 million investment from CK Life Sciences to fund its Phase 2 trial of lead microRNA therapy TTX-MC138.
The stock is currently trading at $14.23, compared with a previous close of $12.22 on the Nasdaq. Shares opened at $18.91 and have traded between $13.18 and $20.99 so far today, with trading volume reaching 7.1 million shares, above the average of 88,000.
Over the past 52 weeks, TransCode shares have ranged between $6.15 and $739.20.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.